TY - JOUR T1 - A Meta-Analysis for Using Radiomics to Predict Complete Pathological Response in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiation JF - In Vivo JO - In Vivo SP - 1857 LP - 1863 DO - 10.21873/invivo.12448 VL - 35 IS - 3 AU - YUNG-SHUO KAO AU - YEN HSU Y1 - 2021/05/01 UR - http://iv.iiarjournals.org/content/35/3/1857.abstract N2 - Background: Preservation of organ function is important in cancer treatment. The ‘watch-and-wait’ strategy is an important approach in management of esophageal cancer. However, clinical imaging cannot accurately evaluate the presence or absence of residual tumor after neoadjuvant chemoradiation. As a result, using radiomics to predict complete pathological response in esophageal cancer has gained in popularity in recent years. Given that the characteristics of patients and sites vary considerably, a meta-analysis is needed to investigate the predictive power of radiomics in esophageal cancer. Patients and Methods: PRISMA guidelines were used to conduct this study. PubMed, Cochrane, and Embase were searched for literature review. The quality of the selected studies was evaluated by the radiomics quality score. I2 score and Cochran’s Q test were used to evaluate heterogeneity between studies. A funnel plot was used for evaluation of publication bias. Results: A total of seven articles were collected for this meta-analysis. The pooled area under the receiver operating characteristics curve of the seven selected articles for predicting pathological complete response in eosphageal cancer patient was quite high, achieving a pooled value of 0.813 (95% confidence intervaI=0.761-0.866). The radiomics quality score ranged from −2 to 16 (maximum score: 36 points). Three out of the seven studies used machine learning algorithms, while the others used traditional biostatistics methods. One of the seven studies used morphology class features, while four studies used first-order features, and five used second-order features. Conclusion: Using radiomics to predict complete pathological response after neoadjuvant chemoradiotherapy in esophageal cancer is feasible. In the future, prospective, multicenter studies should be carried out for predicting pathological complete response in patients with esophageal cancer. ER -